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838in fact, notwithstanding the high baseline patient risk proﬁle, no
procedure-related adverse events were documented.
We acknowledge some limitations of our pivotal study. First, the
comparisons between patients with and without prior SMVR should
be interpreted with caution, because they were not pre-deﬁned in
our initial protocol; nevertheless, they help in settling our patients’
high-risk clinical status while reassuring the feasibility and original
signs of effectiveness of the intervention performed. Second, larger
series and longer term follow-up are warranted to conﬁrm our initial
ﬁndings in this highly selected population. Finally, determining the
most appropriate therapy (i.e., PMVR or surgical reoperation) for
patients with SMVR failure warrants future investigation.
In conclusion, we were able to demonstrate in a preliminary
experience the safety and efﬁcacy of PMVR with the MitraClip
therapy in patients with surgical mitral valve annuloplasty failure.
The promising results demonstrated herewith, therefore, open a
new avenue for further investigation of the role of MitraClip im-
plantation in this complex clinical scenario.*Carmelo Grasso, MDy
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Diuretics and relief of congestion remain the mainstay of therapy in
patients hospitalized with heart failure (HF), regardless of ejection
fraction. However, limited data and established practice guidelines
are available to guide clinicians in the duration and intensity of
inpatient diuresis. In a recent issue of the Journal, van der Meer et al.
(1) add to the growing body of published data indicating that
changes in certain parameters during hospital stay, including renal
function (2), body weight (3), and intravascular volume (4), might
predict post-discharge clinical course. In addition to deﬁning the
ideal surrogate marker(s) to reﬂect clinical euvolemia, future initia-
tives in this area should address the optimal method of decongestion
and the compartment of desired ﬂuid removal (intravascular, extra-
vascular, and so forth). Subpopulations such as patients with chronic
kidney disease, advanced HF, predominant right-sided HF, andHF
with preserved ejection fraction likely warrant special consideration.
Matching the right marker of decongestion with the right patient
population will be an important objective of future studies.
Overall length of stay inHFhas trended down, despite persistently
high rates of post-discharge outcomes (5). This might reﬂect inad-
equate congestion, because approximately 50% of HF patients
lose <2 kg during hospital stay (6). Early readmissions might be
related to hemodynamic perturbations rather than progression ofHF
and thus might be at least partially responsive to aggressive volume
management. Comparative strategies for various metric-guided ap-
proaches to decongestion should be prospectively assessed to opti-
mize post-discharge outcomes in HF. The tremendous economic
and clinical burden of HF demands a more nuanced, systematic, and
standardized approach to the management of congestion.Muthiah Vaduganathan, MD, MPH
Stephen J. Greene, MD
Javed Butler, MD, MPH
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